Tempest Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Tempest Therapeutics
TPST Stock  USD 1.10  0.01  0.92%   
Tempest Therapeutics financial statements provide useful quarterly and yearly information to potential Tempest Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Tempest Therapeutics financial statements helps investors assess Tempest Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Tempest Therapeutics' valuation are summarized below:
Market Capitalization
27.5 M
Earnings Share
(1.60)
There are currently one hundred twenty fundamental trend indicators for Tempest Therapeutics that can be evaluated and compared over time across competition. All traders should double-check Tempest Therapeutics' current fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 14.5 M in 2024. Enterprise Value is likely to drop to about 4.6 M in 2024

Tempest Therapeutics Total Revenue

0.0

Check Tempest Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tempest Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 361.9 K, Interest Expense of 1.5 M or Selling General Administrative of 15.4 M, as well as many indicators such as Price To Sales Ratio of 1.36, Dividend Yield of 0.0 or PTB Ratio of 3.14. Tempest financial statements analysis is a perfect complement when working with Tempest Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Tempest Therapeutics Correlation against competitors.
For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.

Tempest Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets70.9 M51.6 M60.9 M
Pretty Stable
Total Current Liabilities9.6 M9.4 M8.2 M
Slightly volatile
Cash35.9 M39.2 M31 M
Slightly volatile
Common Stock Total Equity22.8 K21.9 K19.4 K
Slightly volatile
Liabilities And Stockholders Equity70.9 M51.6 M60.9 M
Pretty Stable
Non Current Liabilities Total13 M15.4 M11.6 M
Slightly volatile
Total Liabilities22.6 M24.8 M19.8 M
Slightly volatile
Total Current Assets65.6 M40.4 M56.4 M
Pretty Stable
Other Current Liabilities3.2 M3.3 M5.8 M
Pretty Stable
Property Plant And Equipment Net5.6 M10.8 M4.4 M
Slightly volatile
Accounts Payable1.4 M845 K1.6 M
Pretty Stable
Non Current Assets Total5.7 M11.2 M4.6 M
Slightly volatile
Non Currrent Assets Other57 K60 K285 K
Very volatile
Cash And Short Term Investments48.4 M39.2 M55.9 M
Very volatile
Common Stock Shares Outstanding16.2 M15.4 M3.2 M
Slightly volatile
Short Term Investments4.8 M5 M24.5 M
Slightly volatile
Other Current Assets2.1 M1.1 M1.7 M
Pretty Stable
Property Plant And Equipment Gross12.4 M11.8 M5 M
Slightly volatile
Common Stock16.1 K22 K19 K
Pretty Stable
Current Deferred Revenue267.2 K300.6 K327.3 K
Slightly volatile
Short and Long Term Debt Total12.6 M20.7 M5.7 M
Slightly volatile
Net Receivables491.6 K517.5 K2.6 M
Very volatile
Short Term Debt5.5 M5.2 M1.2 M
Slightly volatile
Property Plant Equipment4 M4.8 M3.8 M
Slightly volatile
Capital Lease Obligations7.6 M10.1 M4 M
Slightly volatile
Inventory1.2 M1.8 M918.2 K
Slightly volatile
Capital Stock11.3 K22 K4.2 K
Slightly volatile
Net Working Capital33.6 M31 M21.5 M
Slightly volatile
Long Term Debt8.5 M6.3 M13.7 M
Slightly volatile
Short and Long Term Debt3.4 M3.9 M4.2 M
Slightly volatile

Tempest Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization361.9 K381 K790.7 K
Slightly volatile
Selling General Administrative15.4 M11.7 M17.4 M
Very volatile
Other Operating Expenses31.2 M29.2 M35.1 M
Very volatile
Research Development19.8 M17.5 M16.6 M
Slightly volatile
Total Operating Expenses30.6 M29.2 M34.4 M
Pretty Stable
Cost Of Revenue361.9 K381 K1.8 M
Slightly volatile
Selling And Marketing Expenses325.8 K342.9 K11.1 M
Slightly volatile
Interest Income1.2 M1.1 M257.7 K
Slightly volatile
Reconciled Depreciation512.6 K513 K384.4 K
Slightly volatile

Tempest Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation4.1 M2.5 M4.6 M
Pretty Stable
Begin Period Cash Flow30 M31.2 M24.4 M
Slightly volatile
Depreciation584.3 K381 K635.6 K
Pretty Stable
Capital Expenditures161.5 K170 K1 M
Slightly volatile
Total Cash From Financing Activities36.5 M35.6 M44.2 M
Pretty Stable
End Period Cash Flow38.6 M39.2 M32.6 M
Slightly volatile
Net Borrowings12 M13.5 M14.7 M
Slightly volatile
Other Cashflows From Investing Activities33.6 K34.2 K41.9 K
Slightly volatile
Issuance Of Capital Stock1.2 M1.3 M29.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.361.43104
Slightly volatile
Days Sales Outstanding1 K1.1 K1.3 K
Slightly volatile
Stock Based Compensation To Revenue21.7121.0318.2153
Slightly volatile
Capex To Depreciation0.420.44623.0569
Slightly volatile
Inventory Turnover1.10.921.113
Slightly volatile
Days Of Inventory On Hand429409178
Slightly volatile
Payables Turnover0.430.45090.7868
Very volatile
Sales General And Administrative To Revenue71.6784.6466.3777
Slightly volatile
Average Inventory0.40.450.49
Slightly volatile
Research And Ddevelopement To Revenue30.2344.3232.0579
Slightly volatile
Capex To Revenue0.01480.01561.626
Pretty Stable
Cash Per Share2.422.54484.3 K
Very volatile
Days Payables Outstanding7698103.1 K
Very volatile
Income Quality0.620.92760.7677
Pretty Stable
Net Debt To EBITDA0.760.64530.956
Very volatile
Current Ratio7.984.28898.3749
Slightly volatile
Receivables Turnover0.230.260.2806
Slightly volatile
Graham Number8.218.64515.3 K
Very volatile
Capex Per Share0.01050.0118.259
Slightly volatile
Average Receivables879 K1.5 M995.1 K
Slightly volatile
Revenue Per Share239227165
Slightly volatile
Interest Debt Per Share0.80.8452.214
Very volatile
Debt To Assets0.130.22290.1027
Slightly volatile
Days Of Payables Outstanding7698103.1 K
Very volatile
Ebt Per Ebit1.421.01151.2614
Very volatile
Quick Ratio7.954.28898.3534
Slightly volatile
Net Income Per E B T0.810.930.9876
Slightly volatile
Cash Ratio3.454.16854.6259
Slightly volatile
Days Of Inventory Outstanding429409178
Slightly volatile
Days Of Sales Outstanding1 K1.1 K1.3 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.00621.0453
Slightly volatile
Fixed Asset Turnover0.10.111.0257
Slightly volatile
Debt Ratio0.130.22290.1027
Slightly volatile
Price Sales Ratio1.361.43104
Slightly volatile
Asset Turnover0.01630.01710.0582
Slightly volatile
Operating Cycle1 K1.1 K1.3 K
Slightly volatile

Tempest Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap14.5 M15.3 M127 M
Slightly volatile

Tempest Fundamental Market Drivers

Cash And Short Term Investments39.2 M

Tempest Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Tempest Therapeutics Financial Statements

Tempest Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Tempest Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Tempest Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Tempest Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue300.6 K267.2 K
Cost Of Revenue381 K361.9 K
Stock Based Compensation To Revenue 21.03  21.71 
Sales General And Administrative To Revenue 84.64  71.67 
Research And Ddevelopement To Revenue 44.32  30.23 
Capex To Revenue 0.02  0.01 
Revenue Per Share 227.29  238.66 
Ebit Per Revenue(79.85)(83.84)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Tempest Stock Analysis

When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY